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Any time a medication is pre-
scribed, it is necessary to con-
sider multiple variables in 
constructing a safe and effective 
dosing regimen. One such vari-
able is the renal function, innate 
and sometimes also replaced, 
such as in a dialysis patient. 
Although on the surface this 
may seem a simple task, it is, in 
fact, often quite complex. For 
example, of the drugs covered 
in Seyffart’s Directory of Drug 
Dosage in Kidney Disease, 11% 
lack pharmacokinetic data, and 
60% are excreted extensively in 
the urine (50–100% of the dose). 
Use of Seyffart’s directory greatly 
assists the clinician in making a 
dosing determination.
Dr Seyffart is a nephrologist 
with more than 30 years’ expe-
rience in toxicology, dialysis, 
pharma cokinetics, and the field of 
drug dosing in patients with kid-
ney disease. This book consists of 
a brief introductory chapter con-
taining a discussion of drug ther-
apy in patients with renal disease 
and instructions on the use of the 
bulk of the text, which is com-
posed of monographs for more 
than 1500 drugs, arranged alpha-
betically. The drugs are drawn 
from various European and North 
American pharmacopeias.
Each monograph contains the 
drug’s name, molecular weight, 
usual dosage with normal renal 
function, pharmacokinetics, rec-
ommended dosing adjustments 
based on glomerular filtration 
rate or renal replacement ther-
apy, and potential nephrotoxic-
ity. Of note is the inclusion in the 
pharmacokinetics section of any 
specific metabolic pathways, for 
instance, the cytochrome P450 
enzyme or enzymes involved.
In the introduction, Seyf-
fart highlights the importance 
of drug metabolism, from the 
standpoint of how renal dis-
ease may affect it and how 
drug interactions may lead to 
either increased or decreased 
metabolism. With the advent of 
personalized medicine, it may 
be possible to more precisely 
quantify drug interactions in 
individual patients, which can 
lead to better dosing strategies. 
Thus, if one drug’s metabolism is 
inhibited by a concomitant drug, 
this would magnify a decrease in 
renal clearance; then either an 
alternate, non-interfering drug 
may be substituted, or an even 
greater reduction in dose may be 
required. To evaluate whether a 
metabolism-related drug inter-
action is possible, a website is 
cited (SuperCYP, http://bioin-
formatics.charite.de/supercyp/
index.php?site=drug_interac-
tion_checker).
Seyffart’s is alone among text-
books in its emphasis on drug 
metabolism and individualized 
medicine in determining drug 
dosages in patients with kid-
ney disease. He states that “it 
can be expected that the renal 
patient will belong to the group 
of patients who will benefit most 
from advances in personalized 
medicine.”
The current text is a revision 
and expansion by the author of his 
book of 20 years ago.1 Although 
there are review articles and 
numerous textbooks with chap-
ters that address the topic of drug 
dosing in kidney disease, they 
typically include a much smaller 
number of drugs. There are two 
textbooks comparable to Seyffart’s, 
but they are older and cover fewer 
drugs (2007, 518 drugs;2 and 2009, 
more than 800 drugs3). However, 
both have online editions, whereas 
Seyffart’s does not.
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This book is an essential refer-
ence to all clinicians involved in 
the care of patients with kidney 
disease. Additionally, it is a good 
learning tool for those whose back-
ground in clinical pharmacology 
may not be as extensive or current. 
It provides a concise review of the 
information required for adjusting 
drug dosages.
Let us hope that it will not 
be another 20 years before an 
updated, revised edition of 
Seyffart’s appears.
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